Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00421213 | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | completed | Phase 2 | 50 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00423644 | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | completed | Phase 2 | 17 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01559935 |
| Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma(CarBiRD) |
| completed |
| Phase 2 |
| 74 |
| Weill Medical College of Cornell UniversityOTHER |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT05228470 | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | completed | Phase 2 | 39 | PfizerINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01745588 | Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02458014 | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02619682 | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03349450 | DPX-Survivac and Checkpoint Inhibitor in DLBCL(SPiReL) | completed | Phase 2 | 25 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03015896 | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 36 | David Bond, MDOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01219816 | Multi-centric Study(CHEPRALL) | completed | Phase 2 | 57 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01279694 | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)(CARMYSAP) | completed | Phase 1 / Phase 2 | 72 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01936532 | Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)(IFM2013-06) | completed | Phase 2 | 42 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02558816 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients(OAsIs) | completed | Phase 1 / Phase 2 | 48 | Nantes University HospitalOTHER | 2 | Sep 14, 2026 | clinicaltrials |
| NCT02910583 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)(Captivate) | completed | Phase 2 | 323 | Pharmacyclics LLC.INDUSTRY | 6 | Sep 10, 2026 | clinicaltrials |
| NCT03380026 | Mechlorethamine Induced Contact Dermatitis Avoidance Study(MIDAS) | completed | Phase 2 | 28 | Rochester Skin Lymphoma Medical Group, PLLCOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05900882 | SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | completed | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05508867 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | completed | Phase 2 | 203 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 1, 2026 | clinicaltrials |
| NCT04151667 | Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05254899 | A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)(CLCG-2102) | completed | Phase 2 | 54 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02223208 | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13) | completed | Phase 1 / Phase 2 | 89 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04880434 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)(ZUMA-2) | completed | Phase 2 | 95 | Kite, A Gilead CompanyINDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT02227199 | Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma(BV-ICE) | completed | Phase 1 / Phase 2 | 45 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03409432 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | completed | Phase 2 | 26 | John ReneauOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04569032 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | completed | Phase 2 | 82 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT00461955 | Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation(Expansion) | completed | Phase 2 | 13 | University Hospital, BordeauxOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04827862 | RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy | completed | Phase 2 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06539195 | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | completed | Phase 2 | 59 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis(EMN27) | completed | Phase 2 | 35 | Stichting European Myeloma NetworkNETWORK | 6 | Jul 31, 2026 | clinicaltrials |
| NCT04263584 | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL(COPA-R-CHOP) | completed | Phase 2 | 62 | University Hospital MuensterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03264131 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | completed | Phase 2 | 16 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04975555 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | completed | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07720011 | Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma | completed | Phase 2 | 130 | Peking University People's HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT02337829 | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | completed | Phase 2 | 48 | Acerta Pharma BVINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03568461 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma(ELARA) | completed | Phase 2 | 98 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 9, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01657331 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)(SGN+Benda) | completed | Phase 1 / Phase 2 | 65 | Columbia UniversityOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | completed | Phase 2 | 165 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04113226 | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma(Relyage) | completed | Phase 2 | 1 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05978739 | Evaluating Different Doses of Orelabrutinib in MCL | completed | Phase 2 | 40 | InnoCare Pharma Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02242097 | Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 37 | Northwestern UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03505554 | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma(CRU3) | completed | Phase 2 | 9 | University of Milano BicoccaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02997761 | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | completed | Phase 2 | 19 | University of California, DavisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials